

## A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects with Diabetic Kidney Disease (PROMISS-DKD)



OTHERS	Phase 2
Product Type	Small molecules
Indication	Diabetic Kidney Disease (DKD)
Target	NOX inhibitor
MoA(Mechanism of Action)	Isuzinaxib is an NADPH oxidase (NOX) inhibitor that reduces pathological levels of reactive oxygen species (ROS) by inhibiting NOX enzyme activity, thereby alleviating oxidative stress associated with diabetic kidney disease.
Competitiveness	Isuzinaxib is a first-in-class NADPH oxidase (NOX) inhibitor that targets multiple NOX isoforms to control oxidative stress, inflammation, and fibrosis, making it a promising therapeutic candidate to reduce ROS induced renal damage in diabetic kidney disease. Currently, it is the only clinical-stage drug using this approach for DKD.
Development Stage	Phase 2
Route of Administration	Oral Administration (Capsule)

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*